A higher diameter and a faster enlargement rate of the body’s main pulmonary artery — dubbed the MPA, it carries oxygen-poor blood out of the heart toward the lungs — are independent predictors of poor outcomes among people with pulmonary arterial hypertension (PAH), a new study reports. In predicting…
Researchers in the U.S. have developed a tool to help predict mortality risk in people with chronic lung disease and pulmonary hypertension (PH). The tool, PVD-B65, accounts for risk factors related to both conditions, including age, lung disease type, PH severity, exercise capacity, and blood levels of a heart…
Corsair Pharma successfully completed preclinical studies testing its skin patch delivery system for treprostinil as a treatment for pulmonary arterial hypertension (PAH), and is now planning to launch a Phase 1 clinical trial in the next few months. That’s according to new updates from the U.S.-based company, which…
The National Organization for Rare Disorders (NORD) is seeking participants for its survey-based study Living Rare, which aims to better understand the real-world lived experiences of people in the U.S. with rare diseases. Living Rare, the first large-scale study of its kind in the U.S., seeks to capture the…
Implantation of the Aeson Total Artificial Heart — a device from Carmat designed to mimic the heart’s function — was able to help three advanced heart failure patients with pulmonary hypertension (PH) to become eligible for a heart transplant. The patients, who had previously been considered transplant-ineligible due…
Activation of an immune signaling molecule called STAT6 may lead to pulmonary hypertension (PH) in people with oxygen deprivation due to obstructive sleep apnea, according to a recent study in mice. Obstructive sleep apnea is a common sleep disorder characterized by chronic intermittent hypoxia, or repeated episodes of stopping…
An artificial intelligence (AI)-based algorithm is capable of detecting features of pulmonary hypertension (PH) by analyzing heart sounds recorded with a digital stethoscope, a study found. Eko Health developed the technology with the help of a $2.7 million National Institutes of Health (NIH) grant. The algorithm could…
A single dose of the investigational therapy TX45 improved heart function and blood flow, or hemodynamics, in people with pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF), according to interim results from a Phase 1b clinical trial. The part of the study involving PH-HFpEF patients is completely…
Elevated blood levels of an inflammatory biomarker called the neutrophil-to-lymphocyte ratio (NLR) were associated with a higher risk of death among people with pulmonary hypertension (PH) related to chronic kidney disease (CKD), according to a recent report. “NLR, which is a convenient and inexpensive parameter, may be a novel…
Most adults with pulmonary arterial hypertension (PAH) who switched to Uptravi (selexipag) from other medications in its class achieved stabilization or a lessening of disease severity, according to an analysis of real-world treatment data from the SPHERE registry. Clinical outcomes were also generally good for Uptravi-treated PAH patients…
Cereno Scientific‘s investigational therapy CS1 was well tolerated and showed signs of clinical benefit in people with pulmonary arterial hypertension (PAH), according to top-line data from a Phase 2a clinical trial. The company plans to start discussions with regulatory authorities and will pursue a pivotal clinical trial to…
A global clinical trial evaluating a pulmonary artery denervation (PADN) device in people with pulmonary hypertension (PH) associated with left heart disease has launched in Europe, with the first two patients enrolled at a hospital in Portugal, Pulnovo Medical, the device’s developer, announced. These two adults have undergone…
Get regular updates to your inbox.